Welcome to the 2021 LUPUS CORA Meeting Program Scheduling
The meeting will officially run on Central European Summer Time (CEST), GMT +2
To convert the meeting times to your local time Click Here
No Topic Needed
- Andrea Doria (Italy)
Session Description:
A GSK-sponsored and -organised symposium. GSK products will be discussed.
• Discussing the connection between SLE and lupus nephritis, review treatment strategies that may improve outcomes and consider the concept of disease modification in these diseases
• Discussing the rationale behind B cell-targeted therapy for the complex pathophysiology of SLE and lupus nephritis
• Recognising the importance of considering long-term treatment goals early in the disease course and how these considerations should influence clinical practice
The Prescribing Information for any GSK products discussed will be available at the meeting.
Adverse events should be reported. For UK, reporting forms and information can be found at :https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App store. For Italy, adverse events should be reported to the Agenzia Italiana del Farmaco following the instructions provided at:https://www.aifa.gov.it/content/segnalazioni-reazioni-avvers.
PM-GBL-BEL-WCNT-210028Date of preparation: September 2021
Thinking short - and long-term in lupus nephritis
Supported by GSK
Welcome and introduction
- Andrea Doria (Italy)
Forward thinking in the management of SLE and lupus nephritis
- Andrea Doria (Italy)
Targeted treatments: Connecting SLE and lupus nephritis through pathophysiology
- Hans-Joachim Anders (Germany)
Treatment targets: Balancing short- and long-term goals
- Marta Mosca (Italy)
Panel discussion and audience Q&A
- Andrea Doria (Italy)
- Hans-Joachim Anders (Germany)
- Marta Mosca (Italy)
Summary of discussions
- Andrea Doria (Italy)
- Hans-Joachim Anders (Germany)
- Marta Mosca (Italy)